A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

In a study published in the Journal of the American Medical Association, researchers from Moderna reported that the new combo ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor ...

Moderna is being audited by the PMCPA after yet again being found to have brought discredit on the pharma industry, putting the company on a path that could lead to its suspension from U. | Moderna is ...

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the ...

Learn more about whether Moderna, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Moderna's study, involving 8,000 adults 50 and older, showed the new combo shot generated an immune response against COVID ...

Moderna recently reported a decline in revenue for Q1 2025, but managed to reduce its net loss and improve its loss per share. Despite this, the company's stock price was relatively flat over the ...

Moderna MRNA incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.92. In the year-ago period, the company had reported a loss ...

Moderna is extending its cost savings program into 2027 and targeting a cash breakeven point sometime in 2028 as the larger U.S. vaccine market faces new uncertainties under the Trump administration.

Moderna MRNA2.15%increase; green up pointing triangle logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut around $1.5 billion from its operating expenses. The biotech disclosed the changes alongside news ...